CN Patent

CN106257976B — 人类血浆激肽释放酶抑制剂

Assigned to Biocryst Pharmaceuticals Inc · Expires 2021-02-02 · 5y expired

What this patent protects

本发明公开了如本文所述的式(I)的化合物、以及其药学上可接受的盐。所述化合物是血浆激肽释放酶的抑制剂。还提供了包含本发明的至少一种化合物的药物组合物、以及涉及使用本发明的化合物和组合物来治疗和预防特征在于有害的血浆激肽释放酶活性的疾病和病况的方法。

USPTO Abstract

本发明公开了如本文所述的式(I)的化合物、以及其药学上可接受的盐。所述化合物是血浆激肽释放酶的抑制剂。还提供了包含本发明的至少一种化合物的药物组合物、以及涉及使用本发明的化合物和组合物来治疗和预防特征在于有害的血浆激肽释放酶活性的疾病和病况的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN106257976B
Jurisdiction: CN
Classification: —
Expires: 2021-02-02
Drug substance claim: No
Drug product claim: No
Assignee: Biocryst Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.